Development of a Rapid LC‐MS/MS Method and Its Application for the Pharmacokinetic Analysis of Pacritinib in Rats
Journal of Mass Spectrometry · 2025
DOI: 10.1002/jms.5142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Mass Spectrometry, 2025. Verfasst von Ya Meng Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Pyrimidines. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Science and Technology Project of Zhejiang Province, Wenzhou Basic Scientific Research Project, Fundamental Research Projects of Wenzhou City.
Abstract (Originalsprache)
Pacritinib is a novel medication with certain limitations and unknowns in therapeutic applications. Due to the increased frequency of side effects such as fungal infections, nausea, and vomiting, the potential for drug interactions is significantly heightened. This study aimed to establish a quantitative analysis method for pacritinib and investigate its interactions with other drugs. A quantitative detection method for pacritinib in rat plasma was developed using LC‐MS/MS, with ibrutinib as an internal standard. This method was subsequently applied to pharmacokinetic and drug–drug interaction studies in rats. The method demonstrated good linearity within the range of 1–1500 ng/mL, with an LLOQ of 1 ng/mL. Both intraday and interday precisions (RSD%) were less than 14.52%, and the recovery, matrix effect, and stability met FDA guidelines. The method proved effective for the quantitative detection of pacritinib in rat plasma. Pharmacokinetic studies revealed that isavuconazole significantly inhibited the metabolism of pacritinib compared to voriconazole, resulting in a 2.5‐fold increase in AUC (0− t ) , a 2.6‐fold increase in AUC (0–∞) , and a 3.0‐fold increase in C max . Additionally, the CLz / F value in the isavuconazole group decreased by 67%. This study successfully established a reliable LC‐MS/MS method for detecting pacritinib plasma concentrations in rats. The findings indicate that isavuconazole is more likely to increase pacritinib blood exposure than voriconazole, highlighting the need for caution when combining isavuconazole with pacritinib in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Institute of Molecular Toxicology and Pharmacology, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
ORCID-Profile: Ya Meng Wu
Förderung
- Medical Science and Technology Project of Zhejiang Province
- Wenzhou Basic Scientific Research Project
- Fundamental Research Projects of Wenzhou City
Zitieren
APA
Wu, Y. M., Zheng, K., Huang, L. Y., Ni, J. H., Tang, P. F., Qian, J. C., Xiao, Z. X., & Li, Y. L. (2025). Development of a Rapid LC‐MS/MS Method and Its Application for the Pharmacokinetic Analysis of Pacritinib in Rats. Journal of Mass Spectrometry. https://doi.org/10.1002/jms.5142
Vancouver
Wu YM, Zheng K, Huang LY, Ni JH, Tang PF, Qian JC, et al. Development of a Rapid LC‐MS/MS Method and Its Application for the Pharmacokinetic Analysis of Pacritinib in Rats. Journal of Mass Spectrometry. 2025. doi:10.1002/jms.5142
BibTeX
@article{Wu2025,
author = {Wu, Ya Meng and Zheng, Kai and Huang, Luo Yi and Ni, Jing Huan and Tang, Peng Fei and Qian, Jian Chang and Xiao, Zhong Xiang and Li, Yun Lei},
title = {Development of a Rapid LC‐MS/MS Method and Its Application for the Pharmacokinetic Analysis of Pacritinib in Rats},
journal = {Journal of Mass Spectrometry},
year = {2025},
doi = {10.1002/jms.5142}
}
EUVIMED